© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
The pre-inauguration event on January 19 will be a national moment of unity and remembrance.
With the vaccine rollout going slowly, experts debate delayed second dose and other strategies.
The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.
The decrease is largely due to improved lung cancer treatment, but the impact of COVID-19 is not yet known.
New guidelines recommend focusing on healthy foods but don’t restrict added sugars or alcohol as much as some experts had hoped.
Tips on how to exercise at home or outdoors.
Larger studies suggest people living with HIV might have a modestly higher risk of severe COVID-19, but much remains to be learned.
Anthony Fauci, President-elect Joe Biden and senior legislators were vaccinated publicly to demonstrate their confidence in vaccine safety.
People with HIV, people with cancer and pregnant people can be vaccinated against the coronavirus.
Moderna’s coronavirus vaccine is 94% effective in preventing symptomatic COVID-19—and it may also reduce asymptomatic infection.
Experts encourage HIV-positive people to get the coronavirus vaccine and say there’s no reason to think it won’t be safe.
Pfizer/BioNTech’s coronavirus vaccine is 95% effective for preventing symptomatic illness.
In the United States, an FDA expert advisory panel voted on December 10 to recommend emergency use authorization.
The vaccine from the University of Oxford and AstraZeneca uses a chimpanzee adenovirus vector.
SARS-CoV-2 may have subtle effects on immunological and virological outcomes among people with HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.